Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

Cited by (1,016)

Items 701–800 of 1,016

1. The Effect of Exenatide Once Weekly on Carotid Atherosclerosis in Individuals With Type 2 Diabetes: An 18-Month Randomized Placebo-Controlled Study
   Juraj Koška, Raymond Q. Migrino, Keith C. Chan, Kelly Cooper-Cox, Peter D. Reaven · 2021 · Diabetes Care
2. Effects of Glucagon-Like Peptide-1 Analogue and Fibroblast Growth Factor 21 Combination on the Atherosclerosis-Related Process in a Type 2 Diabetes Mouse Model
   Jae Bum Kim, Gha Young Lee, Hyo Jin Maeng, Hoyoun Kim, Jae Hyun Bae, Kyoung Min Kim, Soo Kyung Lim · 2021 · Endocrinology and Metabolism
3. Mechanism by which dipeptidyl peptidase-4 inhibitors increase the risk of heart failure and possible differences in heart failure risk
   Motoaki Sano · 2018 · Journal of Cardiology
4. The cardiovascular effects of GLP-1 receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action
   Alexiadou, Kleopatra, Hartley, Adam, Tan, Tricia M-M, Khamis, Ramzi · 2024 · Trends in Cardiovascular Medicine
5. Liraglutide and cardiovascular outcomes in a real world type 2 diabetes cohort
   Marco Mirani, Giuseppe Favacchio, Eliseo Serone, Giuseppe Lucisano, Maria Chiara Rossi, Cesare Berra · 2018 · Pharmacological Research
6. Effects of Once-Weekly Semaglutide on Kidney Disease Outcomes by KDIGO Risk Category in the SUSTAIN 6 Trial
   Katherine R. Tuttle, Stephen Charles Bain, Heidrun Bosch‐Traberg, Kamlesh Khunti, Søren Rasmussen, Ekaterina Sokareva, David Z. Cherney · 2024 · Kidney International Reports
7. Association between different GLP-1 receptor agonists and acute pancreatitis: case series and real-world pharmacovigilance analysis
   Hui Guo, Qian Guo, Zhiqiang Li, Ze Wang · 2024 · Frontiers in Pharmacology
8. Comparative cardiovascular safety of glucagon‐like peptide‐1 receptor agonists versus other antidiabetic drugs in routine care: a cohort study
   Elisabetta Patorno, Brendan M. Everett, Allison B. Goldfine, Robert J. Glynn, J. Liu, Chandrasekar Gopalakrishnan, S. C. Kim · 2016 · Diabetes Obesity and Metabolism
9. Clinical Pharmacokinetics and Pharmacodynamics of Albiglutide
   Andreas Brønden, Filip Krag Knop, Mikkel Christensen · 2017 · Clinical Pharmacokinetics
10. Cardiovascular Protection with Anti-hyperglycemic Agents
    PRAKASH C. DEEDWANIA, Tushar Acharya · 2019 · American Journal of Cardiovascular Drugs
11. Heart failure hospitalization with SGLT-2 inhibitors: a systematic review and meta-analysis of randomized controlled and observational studies
    Awadhesh Kumar Singh, Ritu Singh · 2019 · Expert Review of Clinical Pharmacology
12. Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT ‐2 inhibitors and GLP ‐1 receptor agonists
    Aldo Bonaventura, Salvatore Carbone, Dave L. Dixon, Antonio Abbate, Fabrizio Montecucco · 2019 · Journal of Internal Medicine
13. Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting
    Peter Gæde, Pierre Johansen, Christian Klyver Tikkanen, Richard Fulton Pollock, Barnaby Hunt, Samuel J. P. Malkin · 2019 · Diabetes Therapy
14. Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease
    Mafalda Ramos, VOLKER FOOS, Anastasia Ustyugova, Nikco Hau, Pranav Gandhi, Mark Lamotte · 2019 · Diabetes Therapy
15. Risk of acute pancreatitis with incretin-based therapy: a systematic review and updated meta-analysis of cardiovascular outcomes trials
    Awadhesh Kumar Singh, Kalyan Kumar Gangopadhyay, Ritu Singh · 2020 · Expert Review of Clinical Pharmacology
16. Chronic kidney disease as a cardiovascular risk factor
    Rafael Carmena, Juan Francisco Ascaso, Josep Redón · 2020 · Journal of Hypertension
17. Renal protection with glucagon-like peptide-1 receptor agonists
    Martina Vitale, Jonida Haxhi, Tiziana Cirrito, Giuseppe Pugliese · 2020 · Current Opinion in Pharmacology
18. Cardiovascular outcomes with GLP-1 receptor agonists vs. SGLT-2 inhibitors in patients with type 2 diabetes
    Caroline Holm Nørgaard, Liis Starkopf, Thomas Alexander Gerds, Peter Vestergaard, Anders Nissen Bonde, Emil Loldrup Fosbøl, Lars Køber, Nathan D. Wong, Christian Tobias Torp-Pedersen, Christina J-Y Lee · 2021 · European Heart Journal - Cardiovascular Pharmacotherapy
19. Glucose control independent mechanisms involved in the cardiovascular benefits of glucagon-like peptide-1 receptor agonists
    Qinchao Wu, Daisong Li, Chao Huang, Guoliang Zhang, Zheng Wang, Jiane Liu, Haichu Yu, Bingxue Song, Ning Zhang, Bing Li et al. · 2022 · Biomedicine & Pharmacotherapy
20. Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers
    Lili Tong, Sharon G. Adler · 2018 · Postgraduate Medicine
21. Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential
    AL-Noshokaty, Tohada M., Abdelhamid, Rehab, Abdelmaksoud, Nourhan M., Khaled, Aya, Hossam, Mariam, Ahmed, Razan, Saber, Toka, Khaled, Shahd, Elshaer, Shereen Saeid, Abulsoud, Ahmed I. · 2025 · Toxicology Reports
22. 2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases
    Chern‐En Chiang, Kwo-Chang Ueng, Ting‐Hsing Chao, Tsung‐Hsien Lin, Yih-Jer Wu, Kang-Ling Wang, Shih‐Hsien Sung, Hung‐I Yeh, Yi‐Heng Li, Ping‐Yen Liu et al. · 2020 · Journal of the Chinese Medical Association
23. Role of lifestyle and glucagon‐like peptide‐1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases
    Giannakogeorgou, Anna, Roden, Michael · 2024 · Alimentary Pharmacology & Therapeutics
24. Residual cardiovascular risk in coronary artery disease: from pathophysiology to established and novel therapies
    Mattía Galli, Antonio Abbate, Marc P. Bonaca, Filippo Crea, Maurizio Forte, Giacomo Frati, Mario F.L. Gaudino, Charles Michael Gibson, Diana A Gorog, Roxana Mehran et al. · 2026 · Nature Reviews Cardiology
25. A review of glucagon‐like peptide‐1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus
    David R. Owens, Louis Monnier, M Hanefeld · 2017 · Diabetes Obesity and Metabolism
26. NMDAR antagonists for the treatment of diabetes mellitus—Current status and future directions
    Alena Welters, C. Alex Kluppel, Jessica Mrugala, Laura Wörmeyer, Thomas Meißner, Ertan Mayatepek, Christian Heiß, Daniel Eberhard, Eckhard Lammert · 2017 · Diabetes Obesity and Metabolism
27. Incretin-based Drugs and the Incidence of Colorectal Cancer in Patients with Type 2 Diabetes
    Devin Abrahami, Hui Yin, Oriana Hoi Yun Yu, Michaël Pollak, Laurent Azoulay · 2017 · Epidemiology
28. GLP-1 receptor agonists and cardiovascular protection: A class effect or not?
    André Jacques Scheen · 2018 · Diabetes & Metabolism
29. The Clinical Impact of GLP-1 Receptor Agonists in Type 2 Diabetes: Focus on the Long-Acting Analogs
    Helena W. Rodbard · 2018 · Diabetes Technology & Therapeutics
30. Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trials
    Atsushi Tanaka, Koichi Node · 2018 · Cardiovascular Diabetology
31. Synergistic anti-tumor effects of liraglutide with metformin on pancreatic cancer cells
    Ran Lu, Jin Yang, Rui Wei, Jing Ke, Qing Tian, Fei Yu, Junling Liu, Jingjing Zhang, Tianpei Hong · 2018 · PLoS ONE
32. Editor’s Choice- Impact of insulin-treated diabetes on cardiovascular outcomes following high-risk myocardial infarction
    Xavier Rosselló, João Pedro Ferreira, John J.V. McMurray, David A. Aguilar, Marc Alan Pfeffer, Bertram Pitt, Kenneth Dickstein, Nicolas Girerd, Patrick Rossignol, Faiez M. Zannad et al. · 2018 · European Heart Journal Acute Cardiovascular Care
33. Primary Care Management of Patients With Type 2 Diabetes: Overcoming Inertia and Advancing Therapy With the Use of Injectables
    Tricia Santos Cavaiola, Yan Kiriakov, Timothy Reid · 2019 · Clinical Therapeutics
34. The right place for Sulphonylureas today: Part of ‘Review the Series: Implications of recent CVOTs in Type 2 diabetes mellitus’
    David R. Webb, Melanie Jane Davies, Janet Jarvis, Samuel Seidu, Kamlesh Khunti · 2019 · Diabetes Research and Clinical Practice
35. A real-world comparison of cardiovascular, medical and costs outcomes in new users of SGLT2 inhibitors versus GLP-1 agonists
    Insiya B. Poonawalla, Andy Bowe, MICHAEL TINDAL, YUNUS A. MEAH, Phil Schwab · 2021 · Diabetes Research and Clinical Practice
36. Lipid effects of glucagon-like peptide 1 receptor analogs
    Amanda J. Berberich, Robert Alexander Hegele · 2021 · Current Opinion in Lipidology
37. An Overview of Similarities and Differences in Metabolic Actions and Effects of Central Nervous System Between Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) and Sodium Glucose Co-Transporter-2 Inhibitors (SGLT-2is)
    Song Wen, Thiquynhnga Nguyen, Min Gong, Xinlu Yuan, Chaoxun Wang, Jianlan Jin, Ligang Zhou · 2021 · Diabetes Metabolic Syndrome and Obesity
38. Lessons from bariatric surgery: Can increased GLP-1 enhance vascular repair during cardiometabolic-based chronic disease?
    Ehab Bakbak, Daniella C. Terenzi, Justin Z. Trac, Hwee Teoh, Adrian Quan, Stephen A. Glazer, Ori David Rotstein, Mohammed A. Al-Omran, Subodh Verma, David A. Hess · 2021 · Reviews in Endocrine and Metabolic Disorders
39. Glucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma?
    Zaynab Ahmad Mouhammad, Rupali Vohra, Anna Horwitz, Anna‐Sophie Thein, Jens Rovelt Andreasen, Barbara Cvenkel, Pete A. Williams, Augusto Azuara‐Blanco, Miriam Kolko · 2022 · Frontiers in Neuroscience
40. Evidence-Based Management of Diabetes in Older Adults
    Arshag D. Mooradian · 2018 · Drugs & Aging
41. Searching for optimal blood pressure targets in type 2 diabetic patients with coronary artery disease
    Ying H. Shen, Yang Dai, Xiao Qun Wang, Ruiyan Zhang, Lin Lu, Feng Hua Ding, Wei Feng Shen · 2019 · Cardiovascular Diabetology
42. Blood pressure-lowering effects of SGLT2 inhibitors and GLP-1 receptor agonists for preventing of cardiovascular events and death in type 2 diabetes: a systematic review and meta-analysis
    Alhassane Diallo, Miguel Carlos‐Bolumbu, Florence Galtier · 2023 · Acta Diabetologica
43. Safety and Efficacy of GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus with Advanced and End-Stage Kidney Disease: A Systematic Review and Meta-Analysis
    Pajaree Krisanapan, Kanokporn Sanpawithayakul, Pattharawin Pattharanitima, Charat Thongprayoon, Jing Miao, Michael A. Mao, Supawadee Suppadungsuk, Supawit Tangpanithandee, Iasmina M. Craici, Wisit Cheungpasitporn · 2024 · Diseases
44. Renoprotective mechanisms of glucagon-like peptide-1 receptor agonists
    Jake Chen, ME Cooper, Melinda T. Coughlan · 2025 · Diabetes & Metabolism
45. The effect of GLP-1 receptor agonists on renal outcomes: a systematic review and meta-analysis
    Takaya Sasaki, Samantha My-Linh Giang, Jiajia Wu, Takashi Yokoo, Martin Gallagher, Rinaldo Bellomo, Ying Wang · 2025 · Nephrology Dialysis Transplantation
46. Postprandial dysmetabolism: Too early or too late?
    Christos Pappas, Eleni Kandaraki, Sofia Tsirona, Dimitrios Kountouras, Georgia Kassi, Evanthia Diamanti‐Kandarakis · 2016 · HORMONES
47. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
    Yixing Li, Paul D. Rosenblit · 2018 · Current Cardiology Reports
48. The incretin pathway as a therapeutic target in diabetic kidney disease: a clinical focus on GLP-1 receptor agonists
    Michaël J.B. van Baar, Annemarie B. van der Aart, Klaas Hoogenberg, Jaap A. Joles, Hiddo J.L. Heerspink, Daniël H. van Raalte · 2019 · Therapeutic Advances in Endocrinology and Metabolism
49. Cardiovascular outcome trials of the newer anti-diabetic medications
    Tushar Acharya, PRAKASH C. DEEDWANIA · 2019 · Progress in Cardiovascular Diseases
50. Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date
    Sam Matthew Pearson, Noppadol Kietsiriroje, Ramzi Ajjan · 2019 · Diabetes Metabolic Syndrome and Obesity
51. Bibliometric Study of Sodium Glucose Cotransporter 2 Inhibitors in Cardiovascular Research
    Lu Chen, Siyuan Ma, Donghong Hu, Hairuo Lin, Yingqi Zhu, Kaitong Chen, Lin Chen, Cankun Zheng, Jichen Liu, Yulin Liao · 2020 · Frontiers in Pharmacology
52. SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose‐lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic review
    Carlos Escobar, Vivencio Barrios, Juan Cosín, José María Gámez Martínez, Ana Isabel Huelmos Rodrigo, Carolina Ortíz Cortés, Javier Torres Llergo, Carolina Requeijo, Iván Solà, María José Martínez‐Zapata · 2020 · Diabetic Medicine
53. Vascular and metabolic effects of SGLT2i and GLP-1 in heart failure patients
    Michele Correale, Olga Lamacchia, Michele Ciccarelli, Giuseppe Dattilo, Lucia Tricarico, Natale Daniele Brunetti · 2021 · Heart Failure Reviews
54. Use of Glucose-Lowering Agents in Diabetes and CKD
    Radica Z. Alicic, Joshua J. Neumiller, Rodolfo Javier Galindo, Katherine R. Tuttle · 2022 · Kidney International Reports
55. Effects of newer-generation anti-diabetics on diabetic retinopathy: a critical review
    Dimitrios P. Ntentakis, Victor Correa, Anastasia Maria Ntentaki, Eleni Delavogia, Toshio Narimatsu, Nikolaos E. Efstathiou, Demetrios G. Vavvas · 2023 · Graefe s Archive for Clinical and Experimental Ophthalmology
56. Comparative Effectiveness for Glycemic Control in Older Adults with Diabetes
    Michael Quartuccio, Brian J. Buta, Rita Rastogi Kalyani · 2017 · Current Geriatrics Reports
57. Incretin‐based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta‐analysis of randomized controlled trials
    Haining Wang, Ye Liu, Qing Tian, Jin Yang, Ran Lu, Siyan Zhan, Jari K. Haukka, Tianpei Hong · 2017 · Diabetes Obesity and Metabolism
58. Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists
    Sten Madsbad, Jens Juul Holst · 2022 · Cardiovascular Research
59. Association of glucagon-like peptide-1 receptor agonists with cardiovascular and kidney outcomes in type 2 diabetic kidney transplant recipients
    Li‐Chun Lin, Jui‐Yi Chen, Thomas Tao-Min Huang, Vin‐Cent Wu · 2025 · Cardiovascular Diabetology
60. Targeting Diabetic Atherosclerosis: The Role of GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Nonsteroidal Mineralocorticoid Receptor Antagonists in Vascular Protection and Disease Modulation
    Merita Rroji, Nereida Spahia, Andreja Figurek, Goce B. Spasovski · 2025 · Biomedicines
61. Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Narrative Review
    Setor Kwadzo Kunutsor, Samuel Seidu · 2025 · Drugs
62. Lixisenatide: A New Daily GLP-1 Agonist for Type 2 Diabetes Management
    Delilah J. McCarty, Megan Ducker Coleman, Cassie L. Boland · 2017 · Annals of Pharmacotherapy
63. Association of glucagon‐like peptide‐1 receptor agonist use and rates of acute myocardial infarction, stroke and overall mortality in patients with type 2 diabetes mellitus in a large integrated health system
    Robert S. Zimmerman, Todd M. Hobbs, Brian J. Wells, Sheldon Xiaodong Kong, Michael W. Kattan, Jon R. Bouchard, Kevin M. Chagin, Changhong Yu, Brian Sakurada, Alex Milinovich et al. · 2017 · Diabetes Obesity and Metabolism
64. Shifting Paradigms in the Medical Management of Type 2 Diabetes: Reflections on Recent Cardiovascular Outcome Trials
    Faramarz Ismail‐Beigi, Etie S. Moghissi, Mikhail Kosiborod, Silvio E. Inzucchi · 2017 · Journal of General Internal Medicine
65. Advances in the clinical management of type 2 diabetes: a brief history of the past 15 years and challenges for the future
    Naveed A. Sattar · 2019 · BMC Medicine
66. Incretin therapy for diabetes mellitus type 2
    Jens Juul Holst · 2019 · Current Opinion in Endocrinology Diabetes and Obesity
67. Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial
    Venu Menon, Anirudh Kumar, Divyang Rajesh Patel, Julie St. John, Jeffrey Riesmeyer, Govinda J. Weerakkody, Giacomo Ruotolo, Kathy Wolski, Ellen Strauss McErlean, Paul C Cremer et al. · 2020 · BMJ Open Diabetes Research & Care
68. Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials
    Annemarie B. van der Aart‐van der Beek, Daniël H. van Raalte, Cristian Guja, Klaas Hoogenberg, Lisa J. Suchower, Elise Hardy, C. David Sjöström, Hiddo J.L. Heerspink · 2020 · Diabetes Obesity and Metabolism
69. Role of Gliclazide MR in the Management of Type 2 Diabetes: Report of a Symposium on Real-World Evidence and New Perspectives
    Kamlesh Khunti, Mohamed M. Hassanein, Moon‐Kyu Lee, Viswanathan Mohan, Aslam Amod · 2020 · Diabetes Therapy
70. An emerging new concept for the management of type 2 diabetes with a paradigm shift from the glucose-centric to beta cell-centric concept of diabetes - an Asian perspective
    Yoshifumi Saisho · 2020 · Expert Opinion on Pharmacotherapy
71. Evolution of Type 2 Diabetes Management from a Glucocentric Approach to Cardio-Renal Risk Reduction: The New Paradigm of Care
    Stephan Jacob, Andrew J. Krentz, John Eric Deanfield, Lars Rydén · 2021 · Drugs
72. Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial
    Hertzel C. Gerstein, Zhuoru Li, Chinthanie F. Ramasundarahettige, Seung Jae Baek, Kelley R. Branch, Stefano Del Prato, Carolyn S.P. Lam, Renato D. Lópes, Richard E. Pratley, Julio Rosenstock et al. · 2023 · Circulation
73. Novel Antidiabetic Drugs and the Risk of Diabetic Retinopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Artur Małyszczak, Joanna Przeździecka-Dołyk, Urszula Szydełko-Paśko, Marta Misiuk‐Hojło · 2024 · Journal of Clinical Medicine
74. Glucagon-like peptide-1 receptor agonists: new strategies and therapeutic targets to treat atherosclerotic cardiovascular disease
    Tianyu Wang, Juncan Ding, Xinyi Cheng, Qiang Yang, Pengfei Hu · 2024 · Frontiers in Pharmacology
75. Pharmacologic Glycemic Management of Type 2 Diabetes in Adults---2024 Update
    Baiju R. Shah, HARPREET SINGH BAJAJ, Sonia Butalia, Kaberi Dasgupta, Dean T. Eurich, Rahul Jain, Karen Leung, Kerry D. Mansell, Scot H. Simpson · 2024 · Canadian Journal of Diabetes
76. Diabetes for Cardiologists: Practical Issues in Diagnosis and Management
    G.B. John Mancini, ALICE Y.Y. CHENG, Kim Alexander Connelly, DAVID H. FITCHETT, Ronald Goldenberg, Shaun G. Goodman, Lawrence A. Leiter, Eva Lonn, Breay W. Paty, Paul Poirier et al. · 2016 · Canadian Journal of Cardiology
77. Cardiovascular benefits of the newer medications for treating type 2 diabetes mellitus
    Srikanth Yandrapalli, Wilbert S. Aronow · 2017 · Journal of Thoracic Disease
78. Trends in Diabetes Treatment and Monitoring among Medicare Beneficiaries
    Bruce E. Landon, Alan M. Zaslavsky, Jeffrey Souza, John Z. Ayanian · 2018 · Journal of General Internal Medicine
79. Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
    Tricia Santos Cavaiola, Jeremy Pettus · 2018 · Diabetes Metabolic Syndrome and Obesity
80. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs
    Osamah M. Alfayez, Majed S. Al Yami, Mohannad Alshibani, Saad Fallatah, Nasser Alkhushaym, Razan Alsheikh, Nimer S. Alkhatib · 2019 · Primary care diabetes
81. Metformin was associated with lower all-cause mortality in type 2 diabetes with acute coronary syndrome: A Nationwide registry with propensity score-matched analysis
    Chien-Boon Jong, Kuan‐Yu Chen, Mu‐Yang Hsieh, Fang‐Ying Su, Chih‐Cheng Wu, Wen‐Chol Voon, Ching‐Lin Hsieh, Kou‐Gi Shyu, Jun‐Ted Chong, Wei‐Shiang Lin et al. · 2019 · International Journal of Cardiology
82. Management of type 2 diabetes with oral semaglutide: Practical guidance for pharmacists
    Michael P. Kane, Curtis L. Triplitt, Carolina Solis‐Herrera · 2020 · American Journal of Health-System Pharmacy
83. Pharmacotherapy to delay the progression of diabetic kidney disease in people with type 2 diabetes: past, present and future
    Ritwika Mallik, Tahseen Ahmad Chowdhury · 2022 · Therapeutic Advances in Endocrinology and Metabolism
84. Effect of glucagon-like peptide 1 receptor agonists on the renal protection in patients with type 2 diabetes: A systematic review and meta-analysis
    Xiang Li, Yujie Song, Tao Guo, Guiying Xiao, Qiumei Li · 2022 · Diabetes & Metabolism
85. Effects of a Dipeptidyl Peptidase 4 Inhibitor Sitagliptin on Glycemic Control and Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus (GLORIA Trial)
    Daisaku Masuda, Takuya Kobayashi, Masami Sairyou, Hiroyuki Hanada, Tohru Ohama, Masahiro Koseki, Makoto Nishida, Norikazu Maeda, Shinji Kihara, Tatsuya Minami et al. · 2017 · Journal of Atherosclerosis and Thrombosis
86. Comparing once-weekly semaglutide to incretin-based therapies in patients with type 2 diabetes: a systematic review and meta-analysis
    Basem M. Mishriky, Doyle M. Cummings, J.R. Powell, Kerry B. Sewell, Robert J. Tanenberg · 2018 · Diabetes & Metabolism
87. Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus
    Jung‐Im Shin · 2019 · Current Diabetes Reports
88. Acute pancreatitis during GLP-1 receptor agonist treatment. A case report
    Chis, Bogdan Augustin, Fodor, Daniela · 2018 · Medicine and Pharmacy Reports
89. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in high-risk type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
    Xiaomei Chen, Xuge Zhang, Xiang Xiang, Xiang Fang, Shenghong Feng · 2024 · Diabetology & Metabolic Syndrome
90. Perioperative Glucagon-Like Peptide-1 Agonist Use and Rates of Pseudarthrosis After Single-Level Lumbar Fusion: A Large Retrospective Cohort Study
    Vedant Agrawal, Saketh Amasa, Mert Karabacak, Konstantinos D. Margetis · 2024 · Neurosurgery
91. The pharmacodynamics-based prophylactic benefits of GLP-1 receptor agonists and SGLT2 inhibitors on neurodegenerative diseases: evidence from a network meta-analysis
    Ping‐Tao Tseng, Bing‐Yan Zeng, Chih-Wei Hsu, Chao‐Ming Hung, Andre Ferrer Carvalho, Brendon Stubbs, Yen‐Wen Chen, Tien‐Yu Chen, Wei‐Te Lei, Jiann-Jy Chen et al. · 2025 · BMC Medicine
92. Glucagon-like peptide-1 receptor agonists and the endothelium: molecular and clinical insights into cardiovascular protection
    Allegra Battistoni, Linda Piras, Nicola Tartaglia, Francesco Maria Carrano, Claudia De Vitis, Emanuele Barbato · 2025 · Frontiers in Medicine
93. GLP-1 receptor agonists and blood pressure: a state-of-the-art review of mechanisms, evidence, and clinical implications
    Moiz, Areesha, Zolotarova, Tetiana, Filion, Kristian B, Eisenberg, Mark J · 2026 · American Journal of Hypertension
94. Adding prandial GLP-1 receptor agonists to basal insulin: a promising option for type 2 diabetes therapy
    Ronald Goldenberg, Lori Berard · 2017 · Current Medical Research and Opinion
95. Treating Disease Mechanisms in Patients With Heart Failure and Diabetes Mellitus
    Amanda Trang, David A. Aguilar · 2017 · Current Heart Failure Reports
96. Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failure
    Francesco Giorgino, Irene Caruso, Julia Moellmann, Michael Lehrke · 2019 · Metabolism
97. Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM
    Alexis M. McKee, Ali Al-Khazaali, Stewart Gary Albert · 2020 · Journal of the Endocrine Society
98. Report from the 5th cardiovascular outcome trial (CVOT) summit
    Oliver Schnell, Eberhard Standl, Xavier Cos, Hiddo J.L. Heerspink, Baruch Itzhak, Nebojsa M. Lalic, Michael Albrecht Nauck, Antonio Ceriello · 2020 · Cardiovascular Diabetology
99. Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial
    Gregory G. Schwartz, Stephen James Nicholls, Peter Paul Toth, Michael Sweeney, Christopher Halliday, Jan O. Johansson, Norman C.W. Wong, Ewelina Kulikowski, Kamyar Kalantar‐Zadeh, Henry N. Ginsberg et al. · 2021 · Cardiovascular Diabetology
100. What Is the Mechanism Driving the Reduction of Cardiovascular Events from Glucagon-like Peptide-1 Receptor Agonists?—A Mini Review
     Jared Berndt, Soo Liang Ooi, Sok Cheon Pak · 2021 · Molecules